Huahai Pharma has demonstrated remarkable momentum by securing a leading position in the market for lacosamide injection, a third-generation anti-epileptic drug. The product’s sales in China’s public medical institutions surged by over 214% in the first half of 2024, following its inclusion in the National Reimbursement Drug List.
Lacosamide injection, known for its minimal side effects and unique mechanism of action, has become a critical therapeutic option for partial-onset seizures in patients aged four and above. Since its domestic approval and subsequent integration, the drug has rapidly expanded its market footprint.
As of 2025, Huahai Pharma boasts a portfolio of eight approved anti-epileptic drugs, solidifying its position in the competitive pharmaceutical landscape
Zhejiang Huahai Pharmaceutical Co., Ltd. announced the market approval of its lacosamide injection, a blockbuster anti-epileptic drug, which generated over 100 million yuan in sales across China’s public medical institutions in 2023. The product’s revenue surged by 214% year-on-year in the first half of 2024, driven by its inclusion in the National Reimbursement Drug List (NRDL).
As the third new drug approved by the company this year, lacosamide injection (specification: 20ml:0.2g) is classified as a chemical drug category 4, qualifying it for priority procurement in public healthcare institutions under China’s consistency evaluation policy. The medication, designed for partial-onset seizures in patients aged four and above, offers minimal side effects and a novel mechanism of action, positioning it as a critical therapeutic alternative when oral administration is impractical.
Huahai Pharma invested approximately 2.89 million yuan in the drug’s development, with analysts projecting annual sales to reach 115 million yuan. The approval strengthens the company’s neurology portfolio, which now includes eight anti-epileptic therapies.
Industry observers note that domestic generic versions of lacosamide, first introduced by UCB Pharma in 2019, gained momentum after entering the NRDL in 2022 and transitioning to the regular reimbursement catalog in 2024.